Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III Trial of Comparing Combination Administration of Paclitaxel and Cisplatin Versus CEF as Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy

NCT02879513 is registered in ClinicalTrials.gov with RenJi Hospital as lead sponsor.

NCT NCT02879513
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02879513 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III Trial of Comparing Combination Administration of Paclitaxel and Cisplatin Versus CEF as Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy
Lead sponsor
RenJi Hospital
Phase
Phase 3
Overall status
Unknown status
Start date
January 31, 2014
Completion date
December 31, 2022
Enrollment
290 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

inflammatory breast cancer, invasive ductal breast cancer, mucinous breast cancer, tubular breast cancer